Company Analysis
Sign in

Theriva Biologics, Inc. (TOVX)

NYSE: TOVX · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.4
◀ Past 3.6● Present 4.2▶ Future 5.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2011, as filed
Revenue$0.00-100.0%
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equity-154.3%
The recordfrom its filings
Filings in 202635
Newest filingNov 12 · 10-Q
Annual reportMar 12, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted54
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$8.7MCash from operations -$11.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 2, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 6, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 4, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TOVX · research, not advice